Tackling Challenging Mechanisms of Action with De Novo Miniproteins
- Developing an end-to-end AI-MPRO platform to design miniprotein therapeutics against challenging targets, including ion channels and complex multi-protein interfaces that are difficult to address with conventional modalities
- Combining de novo protein design with rapid in silico experimental iteration, enables efficient progression from computational discovery to in vitro and in vivo preclinical proof-of-concept
- Generating compact, highly optimized miniprotein candidates with the potential to deliver first-in-class or best-in-class therapies for targets traditionally considered intractable